OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Dalton on Novel Approaches in Uterine Cancer

April 19th 2017

Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses novel approaches emerging in the field of uterine cancer.

Dr. Siefker-Radtke on FDA Approval of Frontline Atezolizumab in Bladder Cancer

April 18th 2017

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses the FDA approval of the PD-L1 inhibitor atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma as a frontline therapy or following progression occurring ≥12 months after neoadjuvant or adjuvant chemotherapy.

Dr. Osborne Discusses Targeting the HER2 Pathway in Breast Cancer

April 18th 2017

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses targeting the HER2 pathway in breast cancer.

Dr. Mariette on Takeaways from a Study of Esophageal and Gastric Cancer Surgery

April 18th 2017

Christophe Mariette, MD, PhD, surgical oncologist, professor of Surgery, University Hospital of Lille, discusses the main takeaways from a study investigating postoperative mortality after patients undergo surgery for esophageal and gastric cancer.

Dr. Janni on Challenges Facing the Treatment of HER2-Positive Breast Cancer

April 18th 2017

Wolfgang Janni, MD, PhD, University of Ulm, discusses challenges facing the treatment options for patients HER2-positive breast cancer.

Dr. Goy on Lenalidomide as Management for Patients With MCL

April 17th 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the efficacy of lenalidomide (Revlimid) for the treatment of patients with mantle cell lymphoma (MCL).

Dr. Wong on Risk Factors for Hepatitis B-Associated HCC

April 17th 2017

Robert Wong, MD, MS, assistant clinical professor of medicine, director of research and education, Division of Gastroenterology and Hepatology at Alameda Health System, Highland Hospital, discusses the risk factors of hepatitis B-associated hepatocellular carcinoma (HCC).

Dr. Tagawa Discusses the Development of Immunotherapy in Urothelial Cancer

April 14th 2017

Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the development of immunotherapy for patients with urothelial cancer.

Dr. Higano on Docetaxel for Hormone-Sensitive Prostate Cancer

April 14th 2017

Celestia Higano, MD, professor of Medicine and Urology, University of Washington, member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses results of docetaxel (Taxotere) versus hormone therapy in patients with metastatic hormone-sensitive prostate cancer.

Dr. Disis on Immunotherapy in Breast Cancer

April 14th 2017

Mary L. (Nora) Disis, MD, professor of Medicine, Department of Medicine, University of Washington School of Medicine, discusses immunotherapy for patients with breast cancer.

Dr. Heymach on Nivolumab for Lung Cancer

April 14th 2017

John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses efficacy findings with nivolumab (Opdivo) results for patients with metastatic lung cancer.

Potential Challenges in the Future Treatment of Mantle Cell Lymphoma

April 14th 2017

Rekha Rao, PhD, assistant professor, University of Kansas Medical Center, discusses the challenges that exist in the future of treatment for patients with mantle cell lymphoma (MCL).

Dr. Wilky on Immunotherapy Trial in Sarcoma

April 13th 2017

Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses the design of a phase II trial investigating concurrent axitinib (Inlyta) and pembrolizumab (Keytruda) in patients with advanced alveolar soft part sarcoma and other soft tissue sarcomas.

Dr. Quinn on the Future of Treatments for RCC

April 13th 2017

David I. Quinn, MD, MBBS, associate professor of Medicine, medical director of USC Norris Cancer Hospital, on the future of treatments for patients with renal cell carcinoma (RCC).

Dr. Cardoso on the Rationale Behind the Global mBC Vision 2025 Call-to-Action

April 13th 2017

Fatima Cardoso, MD, coordinator, European School of Oncology Breast Cancer Program, Secretary General, European Organization for Research and Treatment of Cancer, director, Breast Unit, Campalimaud Clinical Cancer Center, discusses the rationale behind the Global mBC Vision 2025 Call-to-Action.

Dr. Choueiri on Savolitinib in Papillary Renal Cell Cancer

April 13th 2017

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses savolitinib in papillary renal cell cancer.

Dr. Lane on Identification of BPDCN

April 13th 2017

Andrew A. Lane, MD, PhD, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the identification of a rare blood disorder called blastic plasmacytoid dendritic cell neoplasm.

Dr. Gomella on Ongoing Trials of Immunotherapy in Bladder Cancer

April 12th 2017

Leonard Gomella, MD, professor, chair, Department of Oncology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses ongoing trials of immunotherapy for patients with bladder cancer.

Dr. Thompson on Challenges Facing the Field of Multiple Myeloma

April 12th 2017

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses challenges facing the field of multiple myeloma.

Dr. Goy Discusses Recent Updates in the Treatment of CLL

April 12th 2017

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses recent updates in the treatment of patients with chronic lymphocytic leukemia (CLL).